These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 18219255)
1. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. Zou Y; Zhang RZ; Sabatelli P; Chu ML; Bönnemann CG J Neuropathol Exp Neurol; 2008 Feb; 67(2):144-54. PubMed ID: 18219255 [TBL] [Abstract][Full Text] [Related]
2. An enhancer required for transcription of the Col6a1 gene in muscle connective tissue is induced by signals released from muscle cells. Braghetta P; Ferrari A; Fabbro C; Bizzotto D; Volpin D; Bonaldo P; Bressan GM Exp Cell Res; 2008 Nov; 314(19):3508-18. PubMed ID: 18761340 [TBL] [Abstract][Full Text] [Related]
3. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Baker NL; Mörgelin M; Peat R; Goemans N; North KN; Bateman JF; Lamandé SR Hum Mol Genet; 2005 Jan; 14(2):279-93. PubMed ID: 15563506 [TBL] [Abstract][Full Text] [Related]
4. Reduced cell anchorage may cause sarcolemma-specific collagen VI deficiency in Ullrich disease. Kawahara G; Okada M; Morone N; Ibarra CA; Nonaka I; Noguchi S; Hayashi YK; Nishino I Neurology; 2007 Sep; 69(10):1043-9. PubMed ID: 17785674 [TBL] [Abstract][Full Text] [Related]
9. COL6A1 genomic deletions in Bethlem myopathy and Ullrich muscular dystrophy. Pepe G; Lucarini L; Zhang RZ; Pan TC; Giusti B; Quijano-Roy S; Gartioux C; Bushby KM; Guicheney P; Chu ML Ann Neurol; 2006 Jan; 59(1):190-5. PubMed ID: 16278855 [TBL] [Abstract][Full Text] [Related]
10. Collagen VI status and clinical severity in Ullrich congenital muscular dystrophy: phenotype analysis of 11 families linked to the COL6 loci. Demir E; Ferreiro A; Sabatelli P; Allamand V; Makri S; Echenne B; Maraldi M; Merlini L; Topaloglu H; Guicheney P Neuropediatrics; 2004 Apr; 35(2):103-12. PubMed ID: 15127309 [TBL] [Abstract][Full Text] [Related]
11. Deficiency of tenascin-X causes a decrease in the level of expression of type VI collagen. Minamitani T; Ariga H; Matsumoto K Exp Cell Res; 2004 Jul; 297(1):49-60. PubMed ID: 15194424 [TBL] [Abstract][Full Text] [Related]
12. Expression of collagen VI α5 and α6 chains in human muscle and in Duchenne muscular dystrophy-related muscle fibrosis. Sabatelli P; Gualandi F; Gara SK; Grumati P; Zamparelli A; Martoni E; Pellegrini C; Merlini L; Ferlini A; Bonaldo P; Maraldi NM; Paulsson M; Squarzoni S; Wagener R Matrix Biol; 2012 Apr; 31(3):187-96. PubMed ID: 22226732 [TBL] [Abstract][Full Text] [Related]
13. A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Jimenez-Mallebrera C; Maioli MA; Kim J; Brown SC; Feng L; Lampe AK; Bushby K; Hicks D; Flanigan KM; Bonnemann C; Sewry CA; Muntoni F Neuromuscul Disord; 2006 Oct; 16(9-10):571-82. PubMed ID: 16935502 [TBL] [Abstract][Full Text] [Related]
14. Detection of common and private mutations in the COL6A1 gene of patients with Bethlem myopathy. Lucioli S; Giusti B; Mercuri E; Vanegas OC; Lucarini L; Pietroni V; Urtizberea A; Ben Yaou R; de Visser M; van der Kooi AJ; Bönnemann C; Iannaccone ST; Merlini L; Bushby K; Muntoni F; Bertini E; Chu ML; Pepe G Neurology; 2005 Jun; 64(11):1931-7. PubMed ID: 15955946 [TBL] [Abstract][Full Text] [Related]
15. Aberrant mitochondria in a Bethlem myopathy patient with a homozygous amino acid substitution that destabilizes the collagen VI α2(VI) chain. Zamurs LK; Idoate MA; Hanssen E; Gomez-Ibañez A; Pastor P; Lamandé SR J Biol Chem; 2015 Feb; 290(7):4272-81. PubMed ID: 25533456 [TBL] [Abstract][Full Text] [Related]
16. Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan. Okada M; Kawahara G; Noguchi S; Sugie K; Murayama K; Nonaka I; Hayashi YK; Nishino I Neurology; 2007 Sep; 69(10):1035-42. PubMed ID: 17785673 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Hicks D; Lampe AK; Laval SH; Allamand V; Jimenez-Mallebrera C; Walter MC; Muntoni F; Quijano-Roy S; Richard P; Straub V; Lochmüller H; Bushby KM Brain; 2009 Jan; 132(Pt 1):147-55. PubMed ID: 19015158 [TBL] [Abstract][Full Text] [Related]
18. Molecular consequences of dominant Bethlem myopathy collagen VI mutations. Baker NL; Mörgelin M; Pace RA; Peat RA; Adams NE; Gardner RJ; Rowland LP; Miller G; De Jonghe P; Ceulemans B; Hannibal MC; Edwards M; Thompson EM; Jacobson R; Quinlivan RC; Aftimos S; Kornberg AJ; North KN; Bateman JF; Lamandé SR Ann Neurol; 2007 Oct; 62(4):390-405. PubMed ID: 17886299 [TBL] [Abstract][Full Text] [Related]
19. Fibronectin receptor reduction in skin and fibroblasts of patients with Ullrich's disease. Hu J; Higuchi I; Shiraishi T; Suehara M; Niiyama T; Horikiri T; Uchida Y; Saito A; Osame M Muscle Nerve; 2002 Nov; 26(5):696-701. PubMed ID: 12402292 [TBL] [Abstract][Full Text] [Related]